HUTCHMED (China) Limited HCM
Regular-session close
After hours · Nov 19, 4:00 PM ET
- YTD
- +0.90%
- 1 year
- -7.43%
5D -0.65 (-4.32%)
- Market cap
- 2.34B
- Revenue (ttm)
- 549.12M
- Profit margin
- 3.26%
- EPS (ttm)
- 0.10
- Shares out
- 173.81M
- P/E ratio
- 134.50
- Forward P/E
- 51.89
- YTD return
- +0.90%
- 1-year return
- -7.43%
- Volume
- 37.53K
- Avg volume
- 65.17K
- Open
- 13.97
- Previous close
- 13.99
- Day's range
- 13.41 – 14.00
- 52-week range
- 9.77 – 16.33
- Beta
- 0.50
- Price target
- 21.14 (+57.2%)
- Earnings date
- Mar 4, 2027
Key statistics
- 50-day average
- 14.09
- 200-day average
- 13.17
- Enterprise value
- 1.16B
- Price / sales
- 4.26
- Price / book
- 1.85
- Revenue growth
- 0.20%
- Free cash flow
- -18.88M
- Total cash
- 1.38B
- Total debt
- 94.51M
- Return on equity
- 1.46%
- Short % of float
- 0.26%
Fundamental scorecard
14 of 25 checks passed on HCM’s reported financials
14of 25 checks passed
- Value 3 of 5
- Growth 4 of 5
- Profitability 3 of 5
- Financial health 4 of 5
- Dividend No data
Statements to Jun 30, 2026.
Analyst view
- Target (low)
- 13.60
- Target (mean)
- 21.14
- Target (high)
- 33.27
- Strong buy1
- Buy9
- Hold1
- Sell0
- Strong sell0
Next earnings
Mar 4, 2027
Expected Mar 4, 2027. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 4, 2027 | Dec 30, 2026 | 0.20 | — | — | — |
| Jul 30, 2026 | Jun 30, 2026 | 0.145 | 0.046 | -0.10 | -68.28% |
| Jul 2, 2026 | Mar 31, 2026 | -0.35806 | 0.046 | +0.40 | +112.85% |
| Mar 5, 2026 | Dec 31, 2025 | 2.50 | 0.0005 | -2.50 | -99.98% |
| Aug 7, 2025 | Jun 30, 2025 | 1.46 | 2.60 | +1.14 | +78.08% |
| Jul 2, 2025 | Mar 31, 2025 | -0.31695 | 1.35 | +1.67 | +525.93% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 23, 2026 | Goldman Sachs | main | Neutral | Neutral |
| Jul 7, 2026 | B of A Securities | main | Buy | Buy |
| Mar 10, 2026 | B of A Securities | main | Buy | Buy |
| Sep 22, 2025 | Morgan Stanley | down | Equal-Weight | Underweight |
| Jul 22, 2025 | B of A Securities | main | Buy | Buy |
| Aug 1, 2024 | Goldman Sachs | main | Neutral | Neutral |
About HUTCHMED (China) Limited
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Hong Kong
- Website
- hutch-med.com
News
HUTCHMED Receives China National Medical Products Administration Simultaneous Approval For Two New Drug Applications For Syvik Oral Small Molecule Inhibitor Targeting Spleen Tyrosine Kinase
HUTCHMED Announces China NMPA Approval of SYVIK® (sovleplenib) for the Treatment of Primary Immune Thrombocytopenia and Warm Antibody Autoimmune Hemolytic Anemia
HUTCHMED Highlights HMPL-A830 Pre-Clinical Data Presented at the 38th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS®
HUTCHMED (China) Limited (HCM) Presents at Deutsche Bank Virtual Investor Conference Transcript
Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring Reported Earlier, HUTCHMED’s Oral Syk Inhibitor Sovleplenib Gets US FDA Orphan Drug Designation For Autoimmune Hemolytic Anemia, Its Second After Primary ITP, Eligible For 7 Years Of US Market Exclusivity Upon Approval
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia
HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan
Your note
Sign in to keep a note on HCM — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Schroder Investment Management Group | 0.39% | 682,585 | 9.18M | Sep 29, 2026 |
| State Street Corporation | 0.18% | 318,201 | 4.28M | Sep 29, 2026 |
| Aia Group Ltd | 0.15% | 266,658 | 3.59M | Sep 29, 2026 |
| M&G Plc | 0.14% | 237,882 | 3.20M | Sep 29, 2026 |
| Jane Street Group, LLC | 0.13% | 235,028 | 3.16M | Sep 29, 2026 |
| Amundi | 0.08% | 134,631 | 1.81M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Steward Funds Inc-Steward Values Enhanced International Fund | 0.05% | 84,097 | 1.13M | Jul 30, 2026 |
| SPDR INDEX SHARES Fd.S-State Street SPDR PORT. Developed World ex-US E | 0.04% | 71,242 | 958.20K | Sep 29, 2026 |
| SPDR-EUROPE-SSgA SPDR ETFS Europe I-State Street SPDR MSCI Emerging Ma | 0.03% | 44,991 | 605.13K | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 0.01% | 16,399 | 220.57K | Sep 29, 2026 |
| Dimensional ETF Trust-Dimensional World ex U.S. Core Equity 2 ETF | 0.00% | 2,110 | 28.38K | Jul 30, 2026 |
| Dimensional ETF Trust-Dimensional Emerging Markets Core Equity 2 ETF | 0.00% | 5,574 | 74.97K | Jul 30, 2026 |
